The big news of the week was the launch of Altos labs and their ambitious plan to tackle aging through cell therapies. Altos has recruited a large number of top cell biologists away from academia. That team plus top biotech execs and a $3B war chest make Altos one to watch in coming years. I …
Weekly reads: aging, CRISPR delivery, hair, oocytes, paralysis Read More »
If you celebrate the Thanksgiving holiday I hope you had a nice one and, right before it started a new article popped on the scene about the CRISPR babies. Before we discuss those three gene-edited people, who are now growing up into little kids, we hit a milestone on our YouTube Stem Cell Channel with …
Regenerative reads: 3 CRISPR babies, FDA warning, diabetes, pubs Read More »
This week marked the release of new draft FDA guidance on cell and gene therapies. Is the FDA kind of like the guidance counselor at school or more like the principal? It probably depends on many factors. I also find it funny how pretty much everyone in academia and biotech industry works to be compliant …
Weekly reads: New FDA guidance, brains, MSCs, senescence Read More »
I’m taking a short break today from working on a big grant to put out this weekly reads post including on Sox transcription factors, cord blood paper controversy, and other interesting papers such as one on CTCF and chromatin domains after mitosis that really struck me. I can actually see blue sky today here in …
Weekly reads: CTCF, Sox transcription factors, Clinic fires back, more Read More »
ViaCyte released encouraging data just now on a patient with implanted stem cell-derived pancreas-like device whose diabetes improved. You can read more about this in the Endpoints piece that I linked to in the previous sentence. Stem cells for diabetes; the ViaCyte update The idea of stem cells for diabetes has been more on my …
Quick reaction to milestone ViaCyte data on a diabetes patient Read More »
Although in my years as a stem cell biologist I haven’t yet been in a leadership role at the International Society for Stem Cell Research or ISSCR, unproven stem cell clinics have claimed that I somehow speak for ISSCR. I am just a standard member of the group like thousands of other researchers. In fact, …
Recommended reads: ISSCR guidelines pushback, TB outbreak from regen product, pubs Read More »
It was a couple of years back that researcher He Jiankui claimed he made three “CRISPR babies.” No one would think about doing any kind of rogue gene-editing again, right? Not even somatic gene edits. After all, as far as we know he’s in jail. We still don’t know the health risks that these three …
Ukraine clinic plans to sell CRISPR enhancements: hair color, skin, & breast size Read More »
In the stem cell world some corporate names end up being very similar with the latest example being several companies with the name “BioLife.” Get a BioLife…name I guess BioLife is a catchy term. You’ve got life and biology in there in one name. Let’s deconstruct what’s going on out there with this corporate name. …
Perspectives on BioLife: one name, distinct companies Read More »
Those of you following the arena of unproven stem cells might recognize the name Dr. Joseph Mercola. He’s a promoter of alternative medicine. Over the years his name has also popped related to the marketing of unproven stem cell offerings in various ways. Now the FDA has warned Joseph Mercola on what it says are unapproved …
Sometimes change takes a very long time, but with brain organoids or advocating for better information for patients at Clinicaltrials.gov, after waiting you can see some interesting developments. These are two of the regenerative medicine stories of the week, along with some striking research papers. Clinicaltrials.gov Some of us have been advocating for improvements at …
Regenerative reads: brain organoids, Clinicaltrials.gov change Read More »